A study to identify cells responsible for intrahepatic Soluble Fas ligand (FasL) expression to evaluate which cell types may contribute to liver damage in patients started treatment with tenofovir alafenamide
Latest Information Update: 18 Aug 2021
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 18 Aug 2021 New trial record
- 26 Jun 2021 Results presented at The International Liver Congress 2021